A review of the relationship between parenteral nutrition and metabolic bone disease

Nutrition in Clinical Practice

Volumn 22, Issue 3, 2007, Pages 329-339

  Ferrone, Marcus ^a   Geraci, Matthew ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; AMINO ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOSPORIN; FLUORIDE; GLUCOCORTICOID; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; TACROLIMUS; VITAMIN D; VITAMIN K GROUP; WARFARIN; PHOSPHORUS;

ALUMINUM OVERLOAD; BLOOD EXAMINATION; BONE DENSITY; BONE MINERALIZATION; CALCIUM ABSORPTION; CALCIUM DEFICIENCY; CALCIUM EXCRETION; CALCIUM INTAKE; CALCIUM URINE LEVEL; CATHETER THROMBOSIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; DISEASE COURSE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCIURIA; INFLAMMATION; LACTIC ACIDOSIS; MALNUTRITION; METABOLIC ACIDOSIS; METABOLIC BONE DISEASE; MINERAL DEFICIENCY; OSSIFICATION; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PHOSPHATE DEFICIENCY; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; SHORT BOWEL SYNDROME; URINALYSIS; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY; VITAMIN K DEFICIENCY; BLOOD; BONE; DIFFERENTIAL DIAGNOSIS; METABOLISM;

BONE AND BONES; BONE DISEASES, METABOLIC; CALCIUM; DIAGNOSIS, DIFFERENTIAL; HUMANS; PARENTERAL NUTRITION; PHOSPHORUS; RISK FACTORS;

EID: 34347210353     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426507022003329     Document Type: Review

References (102)

1. Hurley DL, McMahon MM. Long-term parenteral nutrition and metabolic bone disease. Endocrinol Metab Clin North Am. 1990;19:113-131.
2. Pironi L, Labate AM, Pertkiewicz M, et al; ESPEN-Home Artificial Nutrition Working Group. Prevalence of bone disease in patients on home parenteral nutrition. Clin Nutr. 2002;21:289-296.
3. Cohen-Solal M, Baudoin C, Joly F, et al. Osteoporosis in patients on long-term home parenteral nutrition: a longitudinal study. J Bone Miner Res. 2003;18:1989-1994.
4. Koo WW, Sherman R, Succop P, et al. Sequential bone mineral content in small preterm infants with and without fractures and rickets. J Bone Miner Res. 1988;3:193-197.
5. Koo WW, Tsang R. Bone mineralization in infants. Prog Food Nutr Sci. 1984;8:229-302.
6. Klein GL, Cannon RA, Diament M, et al. Infantile vitamin D-resistant rickets associated with total parenteral nutrition. Am J Dis Child. 1982;136:74-76.
7. Toomey F, Hoag R, Batton D, Vain N. Rickets associated with cholestasis and parenteral nutrition in premature infants. Radiology. 1982;142:85-88.
8. Cannon RA, Byrne WJ, Ament ME, Gates B, O'Connor M, Fonkalsrud EW. Home parenteral nutrition in infants. J Pediatr. 1980;96:1098-1104.
9. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999;45:1359-1368.
10. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 1996;17:333-368.
11. Manolagas SC. Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res. 2000;15:1001-1005.
12. Shike M, Harrison JE, Sturtridge WC, et al. Metabolic bone disease in patients receiving long-term total parenteral nutrition. Ann Intern Med. 1980;92:343-350. (Pubitemid 10154810)
13. Klein GL, Targoff CM, Ament ME, et al. Bone disease associated with total parenteral nutrition. Lancet. 1980;2:1041-1044.
14. Shike M, Shils ME, Heller A, et al. Bone disease in prolonged parenteral nutrition: osteopenia without mineralization defect. Am J Clin Nutr. 1986;44:89-98.
15. Ott SM, Kilcoyne RF, Chesnut CH 3rd. Ability of four different techniques of measuring bone mass to diagnose vertebral fractures in postmenopausal women. J Bone Miner Res. 1987;2:201-210.
16. Anderson JB. Nutrition for bone health. In: Mahan LK, Escott-Stump S, eds. Krause's Food, Nutrition and Diet Therapy. 10th ed. Philadelphia, PA: W.B. Saunders; 2000:611-632.
17. Wahner HW. Single- and dual-photon absorptiometry in osteoporosis and osteomalacia. Semin Nucl Med. 1987;17:305-315.
18. Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology. 1982;83:1252-1258.
19. Lipkin EW. Metabolic bone disease. In: Rombeau JL, Rolandelli RH, eds. Clinical Nutrition: Parenteral Nutrition. 3rd ed. Philadelphia, PA: W.B. Saunders; 2000:157-171.
20. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
21. Lipkin EW, Ott SM, Chesnut CH 3rd, Chait A. Mineral loss in the parenteral nutrition patient. Am J Clin Nutr. 1988;47:515-523.
22. Koo WW, Tsang RC, Succop P, Krug-Wispe SK, Babcock D, Oestreich AE. Minimal vitamin D and high calcium and phosphorus needs of preterm infants receiving parenteral nutrition. J Pediatr Gastroenterol Nutr. 1989;8:225-233.
23. Koo WW, Sherman R, Succop P, et al. Fractures and rickets in very low birth weight infants: conservative management and outcome. J Pediatr Orthop. 1989;9:326-330. (Pubitemid 19117753)
24. Fitzgerald KA, MacKay MW. Calcium and phosphate solubility in neonatal parenteral nutrient solutions containing TrophAmine. Am J Hosp Pharm. 1986;43:88-93.
25. Knight P, Heer D, Abdenour G. CaxP and Ca/P in the parenteral feeding of preterm infants. JPEN J Parenter Enteral Nutr. 1983;7:110-114.
26. Niemiec PW Jr, Vanderveen TW. Compatibility considerations in parenteral nutrient solutions. Am J Hosp Pharm. 1984;41:893-911.
27. Poole RL, Rupp CA, Kerner JA Jr. Calcium and phosphorus in neonatal parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1983;7:358-360.
28. Dunham B, Marcuard S, Khazanie PG, Meade G, Craft T, Nichols K. The solubility of calcium and phosphorus in neonatal total parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1991;15:608-611.
29. Barrett EJ, Barrett P. The parathyroid glands and vitamin D. In: Boron WF, Boulpaep EL, eds. Medical Physiology: A Cellular and Molecular Approach. Philadelphia, PA: W.B. Saunders; 2003:1086-1102.
30. Kim Y, Linkswiler HM. Effect of level of protein intake on calcium metabolism and on parathyroid and renal function in the adult human male. J Nutr. 1979;109:1399-1404.
31. Bengoa JM, Sitrin MD, Wood RJ, Rosenberg IH. Amino acidinduced hypercalciuria in patients on total parenteral nutrition. Am J Clin Nutr. 1983;38:264-269.
32. de Vernejoul MC, Messing B, Modrowski D, Bielakoff J, Buisine A, Miravet L. Multifactorial low remodeling bone disease during cyclic total parenteral nutrition. J Clin Endocrinol Metab. 1985;60:109-113.
33. Goodman AD, Lemann J Jr, Lennon EJ, Relman AS. Production, excretion, and net balance of fixed acid in patients with renal acidosis. J Clin Invest. 1965;44:495-506.
34. Karton MA, Rettmer R, Lipkin EW, Ott SM, Chait A. D-lactate and metabolic bone disease in patients receiving long-term parenteral nutrition. JPEN J Parenter Enteral Nutr. 1989;13:132-135.
35. Wood RJ, Bengoa JM, Sitrin MD, Rosenberg IH. Calciuretic effect of cyclic versus continuous total parenteral nutrition. Am J Clin Nutr. 1985;41:614-619.
36. Klein GL, Alfrey AC, Miller NL, et al. Aluminum loading during total parenteral nutrition. Am J Clin Nutr. 1982;35:1425-1429.
37. Ott SM, Maloney NA, Klein GL, et al. Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med. 1983;98:910-914.
38. Goodman WG, Henry DA, Horst R, Nudelman RK, Alfrey AC, Coburn JW. Parenteral aluminum administration in the dog, II: induction of osteomalacia and effect on vitamin D metabolism. Kidney Int. 1984;25:370-375.
39. Foldes J, Rimon B, Muggia-Sullam M, et al. Progressive bone loss during long-term home total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1990;14:139-142.
40. Klein GL, Alfrey AC, Shike M, Sherrard DJ. Aluminum and TPN-related bone disease. Am J Clin Nutr. 1992;55:483-485.
41. Nomura K, Noguchi Y, Yoshikawa T, et al. Long-term total parenteral nutrition and osteoporosis: report of a case. Surg Today. 1993;23:1027-1031.
42. Vargas JH, Klein GL, Ament ME, et al. Metabolic bone disease of total parenteral nutrition: course after changing from casein to amino acids in parenteral solutions with reduced aluminum content. Am J Clin Nutr. 1988;48:1070-1078.
43. Sedman AB, Klein GL, Merritt RJ, et al. Evidence of aluminum loading in infants receiving intravenous therapy. N Engl J Med. 1985;312:1337-1343.
44. Koo WW, Kaplan LA, Bendon R, et al. Response to aluminum in parenteral nutrition during infancy. J Pediatr. 1986;109:877-883.
45. Klein GL, Coburn JW. Total parenteral nutrition and its effects on bone metabolism. Crit Rev Clin Lab Sci. 1994;31:135-167.
46. Young D. FDA aluminum rule poses challenges for industry, pharmacists. Am J Health Syst Pharm. 2004;61:742-744.
47. Gura KM, Puder M. Recent developments in aluminium contamination of products used in parenteral nutrition. Curr Opin Clin Nutr Metab Care. 2006;9:239-246.
48. Bar-Shavit Z, Teitelbaum SL, Reitsma P, et al. Induction of monocytic differentiation and bone resorption by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1983;80:5907-5911.
49. Holick MF. Vitamin D. In: Shils ME, Shike M, eds. Modern Nutrition in Health and Disease. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:376-395.
50. Lo CW, Paris PW, Holick MF. Indian and Pakistani immigrants have the same capacity as Caucasians to produce vitamin D in response to ultraviolet irradiation. Am J Clin Nutr. 1986;44:683-685.
51. Shike M, Sturtridge WC, Tam CS, et al. A possible role of vitamin D in the genesis of parenteral-nutrition-induced metabolic bone disease. Ann Intern Med. 1981;95:560-568.
52. Vieth R. The mechanisms of vitamin D toxicity. Bone Miner. 1990;11:267-272.
53. Verhage AH, Cheong WK, Allard JP, Jeejeebhoy KN. Harry M. Vars Research Award: increase in lumbar spine bone mineral content in patients on long-term parenteral nutrition without vitamin D supplementation. JPEN J Parenter Enteral Nutr. 1995;19:431-436.
54. Larchet M, Garabedian M, Bourdeau A, Gorski AM, Goulet O, Ricour C. Calcium metabolism in children during long-term total parenteral nutrition: the influence of calcium, phosphorus, and vitamin D intakes. J Pediatr Gastroenterol Nutr. 1991;13:367-375.
55. Maillard C, Berruyer M, Serre CM, Dechavanne M, Delmas PD. Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology. 1992;130:1599-1604.
56. Conly JM, Stein K, Worobetz L, Rutledge-Harding S. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol. 1994;89:915-923.
57. Camilo ME, Jatoi A, O'Brien M, et al. Bioavailability of phylloquinone from an intravenous lipid emulsion. Am J Clin Nutr. 1998;67:716-721.
58. Lennon C, Davidson KW, Sadowski JA, Mason JB. The vitamin K content of intravenous lipid emulsions. JPEN J Parenter Enteral Nutr. 1993;17:142-144.
59. Sokoll LJ, Sadowski JA. Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population. Am J Clin Nutr. 1996;63:566-573.
60. Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res. 1993;8:1241-1245.
61. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000;15:515-521.
62. Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut. 2001;48:473-477.
63. Moukarzel ABA, Vargas J, Baron HI, Ament ME. Is fluoride deficiency related to the bone disease of parenteral nutrition? [abstract] Gastroenterology. 1992;102:A568.
64. Caverzasio J, Palmer G, Bonjour JP. Fluoride: mode of action. Bone. 1998;22:585-589.
65. Bouletreau PH, Bost M, Fontanges E, et al. Fluoride exposure and bone status in patients with chronic intestinal failure who are receiving home parenteral nutrition. Am J Clin Nutr. 2006;83:1429-1437.
66. Haderslev KV, Tjellesen L, Haderslev PH, Staun M. Assessment of the longitudinal changes in bone mineral density in patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004;28:289-294.
67. LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990;8:39-51.
68. Reid IR, Ibbertson HK. Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics. Horm Res. 1987;27:200-204.
69. Gnudi S, Butturini L, Ripamonti C, Avella M, Bacci G. The effects of methotrexate (MTX) on bone: a densitometric study conducted on 59 patients with MTX administered at different doses. Ital J Orthop Traumatol. 1988;14:227-231.
70. Sambrook PN, Kelly PJ, Keogh AM, et al. Bone loss after heart transplantation: a prospective study. J Heart Lung Transplant. 1994;13:116-120.
71. Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation. 1994;57:1231-1237.
72. Goldhaber P. Heparin enhancement of factors stimulating bone resorption in tissue culture. Science. 1965;147:407-408.
73. Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density: a prospective matched cohort study. Thromb Haemost. 1996;75:254-257.
74. Fiore CE, Tamburino C, Foti R, Grimaldi D. Reduced axial bone mineral content in patients taking an oral anticoagulant. South Med J. 1990;83:538-542.
75. Pauli RM, Lian JB, Mosher DF, Suttie JW. Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivatives. Am J Hum Genet. 1987;41:566-583.
76. Rosen HN, Maitland LA, Suttie JW, Manning WJ, Glynn RJ, Greenspan SL. Vitamin K and maintenance of skeletal integrity in adults. Am J Med. 1993;94:62-68.
77. Lipkin EW. Metabolic bone disease in gut diseases. Gastroenterol Clin North Am. 1998;27:513-523.
78. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med. 2000;133:795-799.
79. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359-367.
80. Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology. 1992;102:514-519.
81. Jilka RL. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone. 1998;23:75-81.
82. Bischoff SC, Herrmann A, Goke M, Manns MP, von zur Muhlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol. 1997;92:1157-1163.
83. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995;108:417-422.
84. Haugeberg G, Vetvik K, Stallemo A, Bitter H, Mikkelsen B, Stokkeland M. Bone density reduction in patients with Crohn disease and associations with demographic and disease variables: cross-sectional data from a population-based study. Scand J Gastroenterol. 2001;36:759-765.
85. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313-319.
86. Robinson RJ, Iqbal SJ, Abrams K, Al-Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther. 1998;12:699-705. (Pubitemid 28369874)
87. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980;2:1151-1154.
88. Murphy S, Khaw KT, Cassidy A, Compston JE. Sex hormones and bone mineral density in elderly men. Bone Miner. 1993;20:133-140.
89. Takeuchi M, Kakushi H, Tohkin M. Androgens directly stimulate mineralization and increase androgen receptors in human osteoblast-like osteosarcoma cells. Biochem Biophys Res Commun. 1994;204:905-911.
90. Harrison JE, Hitchman AJ, Finlay JM, McNeill KG. Calcium kinetic studies in patients with malabsorption syndrome. Gastroenterology. 1969;56:751-757.
91. Kirschner BS, DeFavaro MV, Jensen W. Lactose malabsorption in children and adolescents with inflammatory bowel disease. Gastroenterology. 1981;81:829-832.
92. Epstein S, Traberg H, Levine G, McClintock R. Bone and mineral status of patients beginning total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1986;10:263-264.
93. Krug SK. Parenteral nutrition: vitamins, minerals, and trace elements. In: Groh-Wargo S, Thompson M, Cox JH, Hartline JV, eds. Nutritional Care for High-Risk Newborns. Rev. 3rd ed. Chicago, IL: Precept Press Inc; 1994:151-175.
94. Pelegano JF, Rowe JC, Carey DE, et al. Simultaneous infusion of calcium and phosphorus in parenteral nutrition for premature infants: use of physiologic calcium/phosphorus ratio. J Pediatr. 1989;114:115-119.
95. Sloan GM, White DE, Murray MS, Brennan F. Calcium and phosphorus metabolism during total parenteral nutrition. Ann Surg. 1983;197:1-6.
96. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 1990;85:456-461.
97. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478-1487.
98. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-236.
99. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition. Am J Clin Nutr. 2002;76:482-488.
100. Nishikawa RA, SS, Siepler JK. Intravenous pamidronate improves bone mineral density in home parenteral nutrition patients [abstract]. Clin Nutr. 2003;22:S88.
101. Raman M, Aghdassi E, Baun M, et al. Metabolic bone disease in patients receiving home parenteral nutrition: a Canadian study and review. JPEN J Parenter Enteral Nutr. 2006;30:492-496.
102. Pazianas M, Compher C, Schiavone-Gatto P, Kinosian BP. Intestinal failure-associated metabolic bone diseases and response to teriparatide. Nutr Clin Pract. 2006;21:605-609.